10x Genomics has completed the acquisition of Proteintech Genomics, a move designed to integrate specialized protein detection capabilities into its existing single-cell and spatial analysis platforms. The transaction, announced on June 10, 2026, marks a strategic effort by the Pleasanton-based company to broaden its multiomics portfolio beyond its established transcriptomic focus.
Founded in 2022, Proteintech Genomics developed a suite of multiplexed proteomic assays that are engineered to function within established single-cell and spatial workflows. The company is perhaps best known for its Human Discovery Panel, which facilitates the simultaneous profiling of 325 protein targets using 347 DNA-barcoded antibodies. This technology allows researchers to harmonize protein and RNA data, providing a more comprehensive view of cellular identity and function.
The integration process relies on the specific design of these DNA-barcoded antibodies, which enable the capture of protein-level information alongside traditional transcriptomic sequencing data. By utilizing these barcodes, the assays ensure that protein measurements remain compatible with the high-throughput sequencing hardware already deployed in laboratories worldwide. This technical alignment minimizes the need for researchers to adopt entirely new, disparate workflows when adding protein analysis to their existing experiments.
Michael Schnall-Levin, chief technology officer, chief strategy officer, and founding scientist at 10x Genomics, emphasized that the integration is a response to the evolving demands of biological research. He noted that while transcriptomic technologies have matured significantly, there remains a substantial opportunity to advance protein-based analysis in tandem with other analytes. The acquisition is expected to support richer multiomic workflows across the 10x product ecosystem.
The Proteintech Genomics technology is already compatible with 10x Genomics’ Flex chemistry, including the Flex Apex assay. This existing interoperability was a primary driver for the deal, as many customers were already utilizing the two companies’ products in combination. By formalizing the relationship, 10x Genomics intends to accelerate the development of higher-plex measurements and more accessible workflows for its user base.
The company also plans to leverage these new capabilities to enhance its Atera spatial platform, which was recently introduced at the American Association for Cancer Research conference. Atera is designed to handle large-scale whole transcriptome analysis, and the addition of protein-detection tools is intended to fulfill the company’s long-term vision for multimodal biological analysis. The integration of these tools remains a priority as 10x Genomics works to scale its spatial biology offerings.
Market analysts have observed that the move addresses a critical growth area in the $11 billion proteomics sector. Puneet Souda, a senior managing director and research analyst at Leerink Partners, noted that the acquisition provides a clear path to accelerating higher-plex content for the Atera platform. However, he also cautioned that the company faces potential headwinds related to the costs of absorbing new technologies and a tightening academic funding environment.
The strategic shift toward proteomics also aligns with 10x Genomics’ broader ambitions to expand into the clinical diagnostics market. The company previously announced partnerships with institutions including Brigham and Women’s Hospital, Dana-Farber Cancer Institute, and the Cancer Research Institute to develop clinical applications. While the current Proteintech Genomics tools are restricted to research use, their inclusion in the 10x portfolio may eventually support more complex translational research and diagnostic development.
Ci Chu, senior vice president of AI-enabled discovery at Xaira Therapeutics, suggested that the move reflects a necessary transition in the field of biological analysis. Chu noted that biology requires more than transcriptomics alone, and that bringing scalable protein measurements into single-cell and spatial biology is a vital step toward creating predictive models of cellular complexity. These models are expected to provide deeper insights into the mechanisms of disease and the function of living systems.
In the coming quarters, the primary watchpoints will be the speed at which the company can integrate these proteomic assays into its existing platforms and the subsequent adoption rates among academic and clinical researchers. Investors will also monitor how the company manages the financial pressures of its ongoing product development cycles against the backdrop of broader market volatility in the life sciences sector.
